CC
KPTI icon

Commodore Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Commodore Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,950,000
Closed -$10.9M – 36
2026
Q1 		$10.9M Buy
+1,950,000
New +$14.9M 0.63% 29
2023
Q1 		– Sell
-129,041
Closed -$6.58M – 37
2022
Q4 		$6.58M Hold
129,041
– – 0.99% 28
2022
Q3 		$10.6M Hold
129,041
– – 1.7% 19
2022
Q2 		$8.73M Sell
129,041
-108,362
-46% -$9.94M 1.85% 17
2022
Q1 		$26.2M Buy
+237,403
New +$29.6M 5.86% 7

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commodore Capital's KPTI Position: Q2 2026 in Review

Commodore Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 1,950,000 shares — an estimated $10.9M sold.

Commodore Capital first reported a position in KPTI in Q1 2022 and held it in 5 quarters. The position peaked at $26.2M in Q1 2022. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Commodore Capital reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Commodore Capital sold 1,950,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $10.9M.
  • Commodore Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and held it in 5 quarters.
  • Commodore Capital's Karyopharm Therapeutics position peaked at $26.2M in Q1 2022.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.